Institution Directory

Clinical trials at University of Michigan

Sites in Ann Arbor, MI

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1230

Shown on this page

Current sort

Live official records

Conditions: Leiomyosarcoma
Interventions: Plasma Collection; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Santa Monica, California • Miami, Florida • Boston, Massachusetts + 6 more

Conditions: Healthy
Interventions: Maya App; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 22 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Skin Basal Cell Carcinoma
Interventions: Best Practice, Educational Activity, Patient Observation, Survey Administration; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Interventions: Biospecimen Collection, Electronic Health Record Review, Goserelin, Leuprolide, Questionnaire Administration; Procedure · Other · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Interventions: Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab, Tucatinib; Drug
Lead sponsor: Carey Anders, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more

Conditions: Idiopathic Short Stature
Interventions: Not listed
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2040
U.S. locations: 38
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 33 more

Conditions: Irritable Bowel Syndrome
Interventions: Diet A - elimination diet, Diet B - healthy eating diet; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Immune Thrombocytopenia
Interventions: rilzabrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Clovis, California • Los Angeles, California • New Orleans, Louisiana + 8 more

Conditions: Health Behaviors, Functional Decline, Chronic Disease, Risk Factors
Interventions: HealthyLifetime; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 30 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Leiomyosarcoma
Interventions: Lurbinectedin, Doxorubicin; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 24
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more

Conditions: Cancer
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 50,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2026
U.S. locations: 30
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 23 more

Conditions: Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
Interventions: CLN-081; Drug
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 18
States / cities: Anaheim, California • Duarte, California • Irvine, California + 12 more

About this University of Michigan institution page

What this page lists: ClinicalTrials.gov records that list University of Michigan in Ann Arbor, MI as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Michigan

Filter and sort this campus

Live official records

Metastatic Leiomyosarcoma Biomarker Protocol

Identification of Biomarkers for Stress Vulnerability and Resilience

Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

A Study to Assess Growth in Children With Idiopathic Short Stature

Defining Objective Markers of Compliance for Dietary Therapies in IBS

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Training Community Members to be Coaches to Deliver the HealthyLifetime Program

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Childhood Cancer Survivor Study

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

About this University of Michigan institution page